Interaction of YAP1 and mTOR promotes bladder cancer progression Retraction in /10.3892/ijo.2024.5638

Xu,Mingxi; Gu,Meng; Zhou,Juan; Da,Jun; Wang,Zhong

doi:10.3892/ijo.2019.4922

Interaction of YAP1 and mTOR promotes bladder cancer progression

Retraction in: /10.3892/ijo.2024.5638

Authors:
- Mingxi Xu
- Meng Gu
- Juan Zhou
- Jun Da
- Zhong Wang
View Affiliations

Affiliations: Department of Urology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, P.R. China
Published online on: November 25, 2019 https://doi.org/10.3892/ijo.2019.4922
Pages: 232-242
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Yes‑associated protein 1 (YAP1) and mammalian target of rapamycin (mTOR) signaling pathways have been found to be deregulated in bladder cancer and accelerate the malignant progression of bladder cancer. However, the crosstalk between YAP1 and mTOR and its role in bladder cancer progression remains unclear. The aim of the present study was to investigate this crosstalk and the results revealed that the expression of YAP1 and mTOR was elevated in bladder cancer tissues compared with that in adjacent normal tissues. Knockdown of either mTOR or YAP1 with siRNA transfection significantly repressed the proliferation ability and induced apoptosis of HT‑1376 and J82 bladder cancer cells, particularly when YAP1 and mTOR were downregulated simultaneously. Upregulation of mTOR increased the mRNA and protein levels of YAP1 and enhanced its nuclear accumulation. In turn, YAP1 upregulation increased mTOR expression, reduced its protein degradation and increased its stability. In addition, immunofluorescence and Duolink assays demonstrated that YAP1 and mTOR were co‑localized in the nucleus. Immunoprecipitation assay demonstrated that the YAP1 protein was able to bind to the mTOR protein. Moreover, YAP1 combined with S‑phase kinase‑associated protein 2 (SKP2) and positively regulated its expression. Furthermore, the promotion of cell growth and inhibition of cell apoptosis induced by YAP1 overexpression were abolished when SKP2 was downregulated in HT‑1376 and J82 cells. Taken together, the findings of the present study indicated that the crosstalk between YAP1 and mTOR plays a pivotal role in accelerating the progression of bladder cancer, which may provide new insights into the role of the YAP1/mTOR axis in the occurrence and development of bladder cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	DeGraff DJ, Cates JM, Mauney JR, Clark PE, Matusik RJ and Adam RM: When urothelial differentiation pathways go wrong: Implications for bladder cancer development and progression. Urol Oncol. 31:802–811. 2013. View Article : Google Scholar
3	Rosenberg JE and Hahn WC: Bladder cancer: Modeling and translation. Genes Dev. 23:655–659. 2009. View Article : Google Scholar : PubMed/NCBI
4	van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, Witjes JA and Zlotta AR: Recurrence and progres-sion of disease in non-muscle-invasive bladder cancer: From epidemiology to treatment strategy. Eur Urol. 56:430–442. 2009. View Article : Google Scholar : PubMed/NCBI
5	Dibble CC and Manning BD: Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat Cell Biol. 15:555–564. 2013. View Article : Google Scholar : PubMed/NCBI
6	Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, et al: PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 73:276–284. 2013. View Article : Google Scholar
7	Liu P, Cheng H, Roberts TM and Zhao JJ: Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 8:627–644. 2009. View Article : Google Scholar : PubMed/NCBI
8	Sathe A and Nawroth R: Targeting the PI3K/AKT/mTOR pathway in bladder cancer. Methods Mol Biol. 1655:335–350. 2018. View Article : Google Scholar
9	Cheng TC, Din ZH, Su JH, Wu YJ and Liu CI: Sinulariolide suppresses cell migration and invasion by inhibiting matrix metalloproteinase-2/-9 and urokinase through the PI3K/AKT/mTOR signaling pathway in human bladder cancer cells. Mar Drugs. 15:E2382017. View Article : Google Scholar : PubMed/NCBI
10	Schettini F, Buono G, Trivedi MV, De Placido S, Arpino G and Giuliano M: PI3K/mTOR inhibitors in the treatment of luminal breast cancer Why, when and to whom? Breast Care (Basel). 12:290–294. 2017. View Article : Google Scholar
11	Gasparri ML, Bardhi E, Ruscito I, Papadia A, Farooqi AA, Marchetti C, Bogani G, Ceccacci I, Mueller MD and Benedetti Panici P: PI3K/AKT/mTOR pathway in ovarian cancer treatment: Are we on the right track? Geburtshilfe Frauenheilkd. 77:1095–1103. 2017. View Article : Google Scholar : PubMed/NCBI
12	Chang L, Graham PH, Ni J, Hao J, Bucci J, Cozzi PJ and Li Y: Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance. Crit Rev Oncol Hematol. 96:507–517. 2015. View Article : Google Scholar : PubMed/NCBI
13	Cheng H, Shcherba M, Pendurti G, Liang Y, Piperdi B and Perez-Soler R: Targeting the PI3K/AKT/mTOR pathway: Potential for lung cancer treatment. Lung Cancer Manag. 3:67–75. 2014. View Article : Google Scholar : PubMed/NCBI
14	Mu DW, Guo HQ, Zhou GB, Li JY and Su B: Oleanolic acid suppresses the proliferation of human bladder cancer by Akt/mTOR/S6K and ERK1/2 signaling. Int J Clin Exp Pathol. 8:13864–13870. 2015.
15	Costa C, Pereira S, Lima L, Peixoto A, Fernandes E, Neves D, Neves M, Gaiteiro C, Tavares A, Gil da Costa RM, et al: Abnormal protein glycosylation and activated PI3K/Akt/mTOR pathway: Role in bladder cancer prognosis and targeted therapeutics. PLoS One. 10:e01412532015. View Article : Google Scholar : PubMed/NCBI
16	Yu FX, Zhao B and Guan KL: Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell. 163:811–828. 2015. View Article : Google Scholar : PubMed/NCBI
17	Zhao B, Li L, Tumaneng K, Wang CY and Guan KL: A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF (beta-TRCP). Genes Dev. 24:72–85. 2010. View Article : Google Scholar : PubMed/NCBI
18	Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu J, Lin JD, Wang CY, Chinnaiyan AM, et al: TEAD mediates YAP-dependent gene induction and growth control. Genes Dev. 22:1962–1971. 2008. View Article : Google Scholar : PubMed/NCBI
19	Liu JY, Li YH, Lin HX, Liao YJ, Mai SJ, Liu ZW, Zhang ZL, Jiang LJ, Zhang JX, Kung HF, et al: Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder. BMC Cancer. 13:3492013. View Article : Google Scholar : PubMed/NCBI
20	Latz S, Umbach T, Goltz D, Kristiansen G, Müller SC and Ellinger J: Cytoplasmatic and nuclear YAP1 and pYAP1 staining in urothelial bladder cancer. Urol Int. 96:39–45. 2016. View Article : Google Scholar
21	Li S, Yu Z, Chen SS, Li F, Lei CY, Chen XX, Bao JM, Luo Y, Lin GZ, Pang SY and Tan WL: The YAP1 oncogene contributes to bladder cancer cell proliferation and migration by regulating the H19 long noncoding RNA. Urol Oncol. 33:427.e1–e10. 2015. View Article : Google Scholar
22	Wei W, Sun HH, Li N, Li HY, Li X, Li Q and Shen XH: WNT5A modulates cell cycle progression and contributes to the chemo-resistance in pancreatic cancer cells. Hepatobiliary Pancreat Dis Int. 13:529–538. 2014. View Article : Google Scholar : PubMed/NCBI
23	Xin B, He X, Wang J, Cai J, Wei W, Zhang T and Shen X: Nerve growth factor regulates CD133 function to promote tumor cell migration and invasion via activating ERK1/2 signaling in pancreatic cancer. Pancreatology. 16:1005–1014. 2016. View Article : Google Scholar : PubMed/NCBI
24	Suriano F, Altobelli E, Sergi F and Buscarini M: Bladder cancer after radiotherapy for prostate cancer. Rev Urol. 15:108–112. 2013.PubMed/NCBI
25	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
26	Park SJ, Lee TJ and Chang IH: Role of the mTOR pathway in the progression and recurrence of bladder cancer: An immunohis-tochemical tissue microarray study. Korean J Urol. 52:466–473. 2011. View Article : Google Scholar : PubMed/NCBI
27	Averous J and Proud CG: When translation meets transformation. The mTOR story Oncogene. 25:6423–6435. 2006. View Article : Google Scholar
28	Das A, Reis F, Maejima Y, Cai Z and Ren J: mTOR Signaling in cardiometabolic disease, cancer, and aging. Oxid Med Cell Longev. 2017:60186752017. View Article : Google Scholar : PubMed/NCBI
29	Peng J, Ma W, Zhou Z, Gu Y, Lu Z, Zhang R and Pan Z: Genetic variations in the PI3K/PTEN/AKT/mTOR pathway predict tumor response and disease-free survival in locally advanced rectal cancer patients receiving preoperative chemoradiotherapy and radical surgery. J Cancer. 9:1067–1077. 2018. View Article : Google Scholar : PubMed/NCBI
30	Zhang YH, Li B, Shen L, Shen Y and Chen XD: The role and clinical significance of YES-associated protein 1 in human osteosarcoma. Int J Immunopathol Pharmacol. 26:157–167. 2013. View Article : Google Scholar : PubMed/NCBI
31	Xia J, Zeng M, Zhu H, Chen X, Weng Z and Li S: Emerging role of Hippo signalling pathway in bladder cancer. J Cell Mol Med. 22:4–15. 2018. View Article : Google Scholar :
32	Lv M, Chen L, Qin T, Zhang X, Liu P and Yang J: Angiomotin promotes breast cancer cell proliferation and invasion. Oncol Rep. 33:1938–1946. 2015. View Article : Google Scholar : PubMed/NCBI
33	Makhlin I, Zhang J, Long CJ, Devarajan K, Zhou Y, Klein-Szanto AJ, Huang M, Chernoff J and Boorjian SA: The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU Int. 108:E84–E90. 2011. View Article : Google Scholar :
34	Frescas D and Pagano M: Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: Tipping the scales of cancer. Nat Rev Cancer. 8:438–449. 2008. View Article : Google Scholar : PubMed/NCBI
35	Chan CH, Morrow JK, Zhang S and Lin HK: Skp2: A dream target in the coming age of cancer therapy. Cell Cycle. 13:679–680. 2014. View Article : Google Scholar : PubMed/NCBI
36	Zhang W, Cao L, Sun Z, Xu J, Tang L, Chen W, Luo J, Yang F, Wang Y and Guan X: Skp2 is overexpressed in breast cancer and promotes breast cancer cell proliferation. Cell Cycle. 15:1344–1351. 2016. View Article : Google Scholar : PubMed/NCBI
37	Zhang S, Chen Q, Liu Q, Li Y, Sun X, Hong L, Ji S, Liu C, Geng J, Zhang W, et al: Hippo signaling suppresses cell ploidy and tumorigenesis through Skp2. Cancer Cell. 31:669–684.e7. 2017. View Article : Google Scholar : PubMed/NCBI